Answer
Administration of abrocitinib (Cibinqo) 200 mg after multiple doses of rifampicin, a strong CYP enzyme inducer, reduced exposure to abrocitinib’s active moiety by approximately 56%.
Sources for this answer
- Cibinqo 200 mg film-coated tabletsPfizer Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 14Document updated
Sources checked